SSTR2 and thyroid tumor: These “fourth-generation analogs” have been reported to show very high affinity for SSTR2, SSTR3, and SSTR5 and intermediate-high affinity for SSTR4, which possibly make them good candidates for thyroid tumor cells that express high levels of SSTR3 or 5, despite low expression of SSTR2 [53].